Abstract
The management of ductal carcinoma in situ (DCIS) has traditionally followed the evidence base for invasive breast cancer using surgery, radiation therapy, and drug therapy to remove the DCIS from the breast and reduce the risk of recurrence for both DCIS and invasive breast cancer. Because of concerns regarding the overtreatment of DCIS, randomized controlled trials have been established to test the outcomes (invasive breast cancer outcomes and patient-reported outcome measures) of active surveillance compared with guideline-concordant care for low-risk (for progression) DCIS. These strategies are undergoing rigorous evaluation to evaluate alternatives to the current management of DCIS.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 69-80 |
| Number of pages | 12 |
| Journal | Surgical oncology clinics of North America |
| Volume | 27 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2018 |
Keywords
- Active surveillance
- Ductal carcinoma in situ (DCIS)
- Endocrine therapy
ASJC Scopus subject areas
- Surgery
- Oncology